Live Sessions

Calculating Risk and Return in Oncology Development Webinar

9AM — 10 am (ET) / 3 pm — 4 pm (CET)

In this session, we investigate macro trends and forecasts in oncology using proprietary EvaluatePharma and Evaluate Omnium metrics, and offer perspectives from our work on the best frameworks and methodologies to quantify risk and return in highly dynamic oncology markets.

This live session will be animated by:

• Dr. Paul Verdin, Head of Custom Solutions at Evaluate
• Henry Barling, Senior Oncology Analyst at Evaluate

Watch recording

Events Preview & Platform Demo Webinar

10AM — 11 am (ET) / 4 pm — 5 pm (CET)

Get an insider’s preview of Inova & BIO’s upcoming Virtual Partnering events in March: Oncology Virtual Partnering 2-5 March and Immunology Virtual Partnering 9-12 March

Our team from Inova, BIO and Evaluate will animate a live session on:

• Who’s attending: company and asset profiles
• A walk-through of Inova’s best-in-class One-on-One Partnering™ platform
• The ins & outs of Virtual Partnering and how to make the most of the event
• Webinar sessions during the events
• Q&A

Watch recording

Events Preview & Platform Demo Webinar

10AM — 11 am (ET) / 4 pm — 5 pm (CET)

Get an insider’s preview of Inova & BIO’s upcoming Virtual Partnering events in March: Oncology Virtual Partnering 2-5 March and Immunology Virtual Partnering 9-12 March

Our team from Inova, BIO and Evaluate will animate a live session on:

• Who’s attending: company and asset profiles
• A walk-through of Inova’s best-in-class One-on-One Partnering™ platform
• The ins & outs of Virtual Partnering and how to make the most of the event
• Webinar sessions during the events
• Q&A

Watch recording

Investing in Global Health Security: Overcoming Challenges in Antibiotic Development Webinar

3PM — 4 pm (CET) / 9 am — 10 am (EST)

This panel will highlight research and collaborations to develop new tools to tackle AMR and provide an update on efforts to facilitate development and uptake of innovation. While these tools may be years from approval, policy engagement to address identified barriers must begin now.

Moderator: Gregory Frank, PhD, Senior Director, Infectious Disease Policy, BIO

Speakers:

• Pierre Daram, Global Project Leader, Associate Director Portfolio Management, Debiopharm
• Silas Holland, Head of External Affairs (Interim), AMR Action Fund
• Jeremy Knox, Policy and Advocacy Lead, Drug Resistant Infections Programme, Wellcome Trust
• Karolina Puskarczyk, Senior Manager, Innovation Policy, Pfizer

Watch recording

Infectious Diseases Event Preview & Virtual Partnering Platform Demo Recording Webinar

5PM — 6 pm (CET) / 11 am — 12 pm (ET)

Watch our webinar recording to:

• Get an overview of the event, including a sneak preview into who’s coming and the plenary session
• Discover the ins and outs of virtual partnering
• See a walk-through of the One-on-One Partnering platform and its key features
• Q&A session

Watch recording

Next Generation Advances in Neuroscience Research Webinar

2PM — 3 pm (CET) / 8 am — 9 am (ET)

This panel brings together executives that are each taking new approaches to treating neurodegenerative disorders. Attendees can expect the session to center around the current challenges in neurodegenerative disease treatment and the anticipated next steps in global research.

Moderator: Danielle Friend, PhD, Senior Director, Science and Regulatory Affairs, BIO

Speakers:

• Tor-Kristian Jenssen, Head, Research & Development, PubGene
• Peter Laivins, Chief Commercial Officer, Alzheon
• Professor Charalampos Tzoulis, Prof. of Neurology & Neurogenetics, Neuro-SysMed

Watch recording

Neuroscience Event Preview & Virtual Partnering Platform Demo Webinar

5PM — 6 pm (CEST) / 11 am — 12 pm (ET)

Watch our webinar recording to:

• Get an overview of the event, including a sneak preview into who’s coming and the plenary session
• Discover the ins and outs of virtual partnering
• See a walk-through of the One-on-One Partnering platform and its key features
• Q&A session

Watch recording

Trends in New Oncology Treatments Webinar

2PM — 2:45 pm (CET) / 8 am — 8:45 am (ET)

Record number of new oncology treatments have been approved in recent years, bringing new treatment options to patients.  Although recent progress has deepened our understanding of the disease and has also brought on unprecedented new possibilities for personalized medicine, there are still many cancer types for which there are no, or minimally, effective therapy. Leaders in the field will discuss the latest breakthroughs in oncology research, the impact of COVID-19 on oncology drug development and insights on future trends in oncology treatment and the financial landscape for these promising new therapies.

The panel will focus on:

• Latest development in oncology R&D
• Including Real World Evidence and its uses to glean information about patients with molecular subsets of cancers
• Advancements in Cell Therapy
• What was hot at ESMO
• Perspectives on investment landscape in oncology
• AI/ML

Watch recording